Development of novel core-shell dual-mesoporous silica nanoparticles for the production of high bioavailable controlled-release fenofibrate tablets

Zhao, Zongzhe; Gao, Yu; Wu, Chao; Hao, Yanna; Zhao, Ying; Xu, Jie

doi:10.3109/03639045.2015.1039018

Cited by 22 publications

(8 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was chosen as a model drug and was loaded onto csMSN by the adsorption equilibrium method [16]. The drug loading of csMSN was concentration-dependent.…”

Section: Methodsmentioning

confidence: 99%

RETRACTED ARTICLE: Effect of Paclitaxel-Mesoporous Silica Nanoparticles with a Core-Shell Structure on the Human Lung Cancer Cell Line A549

Wang

Liu

2017

Nanoscale Res Lett

Self Cite

View full text Add to dashboard Cite

A nanodrug delivery system of paclitaxel-mesoporous silica nanoparticles with a core-shell structure (PAC-csMSN) was used to increase the dissolution of paclitaxel (PAC) and improve its treatment of lung cancer. PAC was loaded into the core-shell mesoporous silica nanoparticles (csMSN) by the adsorption equilibrium method and was in an amorphous state in terms of its mesoporous structure. In vitro and in vivo studies showed that csMSN increased the dissolution rate of PAC and improved its lung absorption. The area under concentration-time curve (AUC) value of PAC-csMSN used for pulmonary delivery in rabbits was 2.678-fold higher than that obtained with the PAC. After continuous administration for 3 days, a lung biopsy showed no signs of inflammation. Cell apoptosis results obtained by flow cytometry indicated that PAC-csMSN was more potent than pure PAC in promoting cell apoptosis. An absorption investigation of PAC-csMSN in A549 cells was carried out by transmission electron microscopy (TEM) and laser scanning confocal microscopy (LSCM). The obtained results indicated that the cellular uptake was time-dependent and csMSN was uptaken into the cytoplasm. All these results demonstrate that csMSN have the potential to achieve pulmonary inhalation administration of poorly water-soluble drugs for the treatment of lung cancer.

show abstract

“…It was chosen as a model drug and was loaded onto csMSN by the adsorption equilibrium method [16]. The drug loading of csMSN was concentration-dependent.…”

Section: Methodsmentioning

confidence: 99%

RETRACTED ARTICLE: Effect of Paclitaxel-Mesoporous Silica Nanoparticles with a Core-Shell Structure on the Human Lung Cancer Cell Line A549

Wang

Liu

2017

Nanoscale Res Lett

Self Cite

View full text Add to dashboard Cite

show abstract

“…The dissolution medium was an aqueous solution containing 1% of sodium dodecyl sulfate. 33 The temperature was maintained at 37°C ± 0.5°C, and the paddle speed was 100 rpm. The sample specification was 100 mg, and the medium volume was 1,000 mL.…”

Section: Methodsmentioning

confidence: 99%

Development of a tin oxide carrier with mesoporous structure for improving the dissolution rate and oral relative bioavailability of fenofibrate

Bai

et al. 2018

DDDT

Self Cite

View full text Add to dashboard Cite

BackgroundBiopharmaceutics classification system class II drugs have low solubility, which limits their extent and speed of absorption after oral administration. Over the years, mesoporous materials have been widely used to increase the dissolution rate and oral relative bioavailability of poorly water-soluble drugs.ObjectivesIn order to improve the dissolution rate and increase oral relative bioavailability of the poorly water-soluble drugs, a tin oxide carrier (MSn) with a mesoporous structure was successfully synthesized.MethodsIn this study, MSn was synthesized using mesoporous silica material (SBA-15) as the template. Fenofibrate (FNB) was adsorbed into the channels of MSn by an adsorption method. Characterizations of the pure FNB, MSn, physical mixture of the drug and MSn (PM; 1:1) and FNB-loaded MSn (FNB-MSn) samples were carried out by the scanning electron microscopy (SEM), transmission electron microscopy (TEM), N2 adsorption/desorption, powder X-ray diffractometer (PXRD), differential scanning calorimetry (DSC) and Fourier transform infrared (FT-IR) spectroscopy. Cytotoxicity assay (MTT) was used to evaluate the cytotoxicity of MSn. In vitro dissolution studies were performed to investigate the dissolution rate of FNB-MSn. In vivo pharmacokinetic studies were used to investigate the changes of plasma drug concentrations of FNB-MSn tablets and commercial FNB tablets in rabbits.ResultsDetailed characterization showed that FNB in the channels of MSn was present in an amorphous state. The in vitro release tests demonstrated that MSn with a good biocompatibility could effectively enhance the dissolution rate of FNB. Pharmacokinetic results indicated that MSn significantly increased the oral relative bioavailability of FNB.ConclusionMSn can be regarded as a promising carrier for an oral drug delivery system.

show abstract

“…DMSN‐FF and CMSN‐FF showed drug release percentage of 35 % and 65 % respectively, within 5 min. It is clear that oral drug bioavailability was enhanced by DMSN . The more interesting feature of silica nanostructure is the availability of hydroxy functional group which can facilitate the easy functionalization of the surface of nanostructure and makes them as an excellent stimulus responsive nanocarriers for domestic drug, gene delivery, and biomedical applications.…”

Section: Ff Nanoformulation Techniques and Literature Reportsmentioning

confidence: 99%

Solubility and Bioavailability of Fenofibrate Nanoformulations

Kumar

2020

ChemistrySelect

View full text Add to dashboard Cite

Dedicated to my parents, family, all my teachers and friends.Fenofibrate is a poorly water soluble lipid-regulating drug used to control triglyceride and cholesterol levels in blood plasma. However, due to its poor aqueous solubility, it has poor therapeutic effectiveness. Recently, several approaches based on nanotechnology have been developed to enhance the water solubility, dissolution, bioavailability, and control release of Fenofibrate. However, very few of these innovative formulations have reached the stage of clinical trials and only few have commercialized. Here, we systematically review the techniques such as milling, antisolvent precipitation, sonication, supercritical fluid techniques, electrospray, self-emulsifying drug delivery, lipid-based nanoparticle, and silica nanostructurebased formulation used to enhance bioavailability of Fenofibrate. We have reviewed the progress in Fenofibrate nanoformulations, commercial products, and future challenges for further investigation.[a] Dr.

show abstract

Development of novel core-shell dual-mesoporous silica nanoparticles for the production of high bioavailable controlled-release fenofibrate tablets

Cited by 22 publications

References 39 publications

RETRACTED ARTICLE: Effect of Paclitaxel-Mesoporous Silica Nanoparticles with a Core-Shell Structure on the Human Lung Cancer Cell Line A549

RETRACTED ARTICLE: Effect of Paclitaxel-Mesoporous Silica Nanoparticles with a Core-Shell Structure on the Human Lung Cancer Cell Line A549

Development of a tin oxide carrier with mesoporous structure for improving the dissolution rate and oral relative bioavailability of fenofibrate

Solubility and Bioavailability of Fenofibrate Nanoformulations

Contact Info

Product

Resources

About